“Biotech, MedTech, HealthTech: Austin Can Become a Leader”

Scott Collins

Panel moderated by Scott Collins, Ph.D.
Presented by

BioAustin-new   StD_NeuroTexas_linearlogo_2cBlue


Tuesday, April 7, 2015
Stateside Theater, Downtown Austin
5:15 p.m. – Doors and Bar Open
6:00 p.m. – Presentation, Q&A
7:00 p.m. – Reception
Free and open to the public

Austin is one the leading technology cities in the world–but not in biotech (yet). Austin’s strengths in other areas of technology, its talented workforce, a world-class research university, two great hospital systems, an attractive climate for business, and even some notable biotech company success stories have not yet resulted in the creation of large, vibrant biotech sector. However, Austin can become a great biotech city, producing products, services, and knowledge that increase the quality and duration of lives. The creation of the Dell Medical School may be the spark that was needed to ignite the growth of the Austin biotech community, but it will also require vision and effort from industry and government to create a world-class biotech sector. The panelists will discuss how Austin’s many strengths–companies, institutions, technologies, and even culture–can be leveraged and its creative talents harnessed to develop innovative, disruptive technologies and systems that change lives and society. The speakers will also address how this will benefit Austin–jobs, economy, quality of healthcare, and more–and how Austinites can contribute to building our biotech sector.

Submit your request for the presenter(s) to address a particular topic or issue


Scott is a serial entrepreneur working to change the world in the biotechnology space. He serves on the Board of Directors for BioAustin, a non-profit group formed 2013 to make Austin the best place to start or grow a Life Science company. He serves on the Scientific Advisory Board for the New Organ Prize, an X-like prize for liver engineering. He is CEO of Collins Biomedical, a consultancy that helps Biotech and Healthtech companies succeed faster by applying modified lean startup principles. And he is a partner and CTO at TeVido Biodevices, a company using bioprinting techniques to form custom tissues using a patient’s own cells. He holds 3 degrees from the University of Texas at Austin and is known as an accomplished leader, innovator, and entrepreneur with a successful company exit.

Jeanette Hill, Ph.D.
Spot On Sciences
Jeanette is Founder and CEO of Spot On Sciences, which develops medical devices to allow a blood sample to be taken at home with a fingerstick. She has more than 20 years experience in research and management positions in small and large biotech companies, developing products for preclinical drug testing.

She received a Ph.D. in Bio-organic Chemistry at Washington University in St. Louis with research in protein engineering and completed post-doctoral research on liver disease and diabetes at Case Western Reserve University and Washington University Medical School.
Spot On Sciences has been awarded over $2M in Small Business Innovation Research (SBIR) awards from the Defense Advanced Research Projects Agency (DARPA) and National Institute of Health (NIH) to develop revolutionary products for blood sampling. The company has won many innovation and business awards including: Cartier Awards N.A. 2011, SXSW Interactive 2013, RISE Global pitch winner 2013, 1776 Challenge 2014, SXSW pitch 2014, Astia Global winner 2014, Austin A-List Hottest Start-ups 2014, Get In the Ring N.A. winner 2014.

Mini Kahlon, Ph.D.
The University of Texas Dell Medical School
Dr. Kahlon is Vice Dean for Partnerships & Strategy at The University of Texas Dell Medical School. In this key role, Mini builds the ecosystem of partners the Dell Medical School needs to achieve its transformative goals for medicine and health. She is working to set the early priorities of the medical school, and helping to align leaders and stakeholders with a common vision.
Prior to joining the medical school, Mini was Executive Director and Chief Information Officer for the Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF). At CTSI, she led national initiatives focused on health information technology; statewide initiatives to accelerate research and aggregate data from across the University of California system; and multi-partner grants funded by the NIH, National Science Foundation (NSF) and Patient-Centered Outcomes Research Institute (PCORI) that used data and technology to improve research and health.
Mini also brings management experience from Silicon Valley startups working on award-winning software and technologies, as well as the philanthropic social change sector working to improve education. Mini is a graduate of Bryn Mawr College and received her PhD in Neuroscience from UCSF.

Christopher Mueller, Ph.D.
Lab7 Systems, Inc.
Chris is the Founder and CTO of Lab7 Systems, Inc., a software company focused on creating laboratory informatics solutions to meet the needs of today’s data intensive life science and clinical applications. Throughout his industrial and academic careers, Chris’ passion has been leveraging scientific, high-performance computing solutions to increase scientific productivity across a wide range of applications and user-bases. Based in Austin, Chris is committed making Central Texas a hub for the life sciences and scientific computing. He received his B.S in Computer Science from the University of Notre Dame and his M.S. and Ph.D. in Computer Science with a minor in Bioinformatics from Indiana University.

Tim Sullivan
Mystic Pharmaceuticals
Over the past 37 years, Tim has created novel technologies, products, and services and grown seven companies, three of which were acquired by major corporations. Tim is co-inventor of Mystic’s novel drug delivery technology platforms and responsible for defining both the technological and strategic direction of Mystic. He has recruited and led a highly accomplished team of scientists, engineers and business professionals through early stage R&D programs, clinical trials and the deployment of a cGMP production facility for Mystic’s innovative delivery technologies. He holds ten issued/pending patents in the field of drug/biologic packaging and delivery.


Douglas Fox, M.D.
NeuroTexas Institute
Dr. Fox is board certified in neurological surgery. He grew up in St. Louis, Missouri. After finishing his undergraduate degree at Wake Forest University in 1995. He went on to complete his medical degree at Washington University in 1999. Dr. Fox remained at Washington University for his residency training in neurosurgery and graduated in 2005. Following his residency, he completed two additional years of training with fellowships in cerebrovascular surgery with Robert Spetzler, M.D. and complex spinal surgery with Volker K Sonntag, M.D. at the Barrow Neurological Institute.
His clinical interests include surgery for complex spinal disorders, brain tumor surgery and cerebrovascular surgery. Dr. Fox has published widely and maintains an active research interest in cerebrovascular physiology and the development of new surgical technologies to improve neurosurgical care.